HEFEI LIFEON PHARMACEUTICAL CO., LTD.

Founded in 2002, Hefei Lifeon Pharmaceutical Co.,Ltd. is a joint-stock enterprise integrating drug R&D, manufacturing and sales. It owns 5 pharmaceutical industrial enterprises and 1 pharmaceutical retail chain enterprise. It covers the full range of production including APIs, traditional Chinese medicine extracts, Chinese patent medicines and chemical pharmaceutical preparations, etc. Moreover, Lifeon has the largest osmotic pump preparation production base in China.In 2013, the post-doctoral research workstation officially started operation.In 2018, Succimer API passed FDA inspection with zero deficiencies.In 2020, Lifeon listed on Shenzhen Stock Exchange.In 2023, a new API factory called Hefei Dayu Pharmaceutical Co.,Ltd obtained the DML and started production.In 2024, Doxazosin Mesylate, and Prilocaine APIs passed NMPA GMP inspection. Succimer API received renewed FDA certification. Completed registration applications for 6 API varieties within the same year.In the past 23 years, Lifeon has obtained numerous honors, including national high-tech enterprise, innovative enterprise in Anhui Province, enterprise technology center in Anhui Province, engineering technology research center for sustained and controlled release of drugs in Anhui Province, etc. For eight consecutive years, it has been selected as one of the “China's Top 100 Chemical and Pharmaceutical Industrial Enterprises with Comprehensive Strength”.